![Navigating Site Activation Strategy Under the EU Clinical Trials Regulation](https://www.precisionformedicine.com/hs-fs/hubfs/PfM%20Website/PfM%20-%20Services%20-%20Specialty%20Labs%20Services/Specialty%20Lab%20Services%20in%20Europe/european-flag.jpg?width=396&height=224&name=european-flag.jpg)
![Chris, Ingram Avatar](https://www.precisionformedicine.com/hs-fs/hubfs/PfM%20Website/Headshots/Headshots%20no%20background/Chris%20Ingram.webp?width=100&height=100&name=Chris%20Ingram.webp)
Chris Ingram
Chris Ingram, BSc (Hons) is Head of Regulatory Consultancy (Europe) for Precision for Medicine. Chris received his BSc(Hons) in immunology and pharmacology from the University of Strathclyde and has since spent over 21 years working in regulatory affairs with a focus on clinical development. Chris’ regulatory expertise covers clinical development across all phases, regulatory strategy, marketing authorisations, scientific advice, orphan drug designation and paediatric investigation plans across a wide variety of therapeutic areas, including but not limited to, oncology, CNS, metabolic, endocrinology, analgesia and cardiovascular.
-
Read: Navigating Site Activation Strategy Under the EU Clinical Trials Regulation Navigating Site Activation Strategy Under the EU Clinical Trials Regulation
-
Read: The 10 Proposed Revisions to UK Clinical Trial Regulations Discover
-
Read: Proposed Legislative Changes for UK Clinical Trials Discover
-
Read: Implications of EU-CTR Regulation 536/2014 Discover
-
Read: BREXIT: What has Changed in the United Kingdom Clinical Trial Regulatory Landscape? Discover
Loading...
You've reach the end